Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
10 May 24
8-K
Results of Operations and Financial Condition
17 Apr 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
8-K
Results of Operations and Financial Condition
12 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
29 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Feb 24
8-K
Results of Operations and Financial Condition
8 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Results of Operations and Financial Condition
15 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
8 Nov 23
8-K
Other Events
2 Oct 23
8-K
Results of Operations and Financial Condition
25 Sep 23
8-K
Results of Operations and Financial Condition
11 Sep 23
8-K
Results of Operations and Financial Condition
7 Sep 23
8-K
Results of Operations and Financial Condition
30 Aug 23
8-K
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
23 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
9 Aug 23
S-8
Registration of securities for employees
23 Jun 23
8-K
Results of Operations and Financial Condition
8 Jun 23
8-K
Departure of Directors or Certain Officers
25 May 23
8-K
Other Events
16 May 23
424B5
Prospectus supplement for primary offering
12 May 23
8-K
Ani Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
12 May 23
8-K
Ani Pharmaceuticals Announces Proposed Public Offering of Common Stock
11 May 23
424B5
Prospectus supplement for primary offering
11 May 23
DEFA14A
Additional proxy soliciting materials
8 May 23
8-K
Departure of Directors or Certain Officers
8 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
8 May 23
DEFA14A
Additional proxy soliciting materials
11 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
ARS
2022 FY
Annual report to shareholders
11 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
Latest ownership filings
4
Meredith Cook
13 May 24
4
Chad Gassert
3 May 24
4
Muthusamy Shanmugam
22 Apr 24
144
Notice of proposed sale of securities
19 Apr 24
144
Notice of proposed sale of securities
18 Apr 24
4
Muthusamy Shanmugam
17 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Meredith Cook
15 Apr 24
4
James G. Marken
11 Apr 24
4
STEPHEN P. CAREY
11 Apr 24
3
Thomas Andrew Rowland
8 Apr 24
4
Chad Gassert
2 Apr 24
4
STEPHEN P. CAREY
25 Mar 24
4
James G. Marken
25 Mar 24
4
Nikhil Lalwani
25 Mar 24
SC 13D/A
Meridian Venture Partners II GP, L.P.
14 Mar 24
4
Meredith Cook
13 Mar 24
4
Chad Gassert
13 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
Muthusamy Shanmugam
11 Mar 24
4
STEPHEN P. CAREY
11 Mar 24
4
Nikhil Lalwani
8 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
James G. Marken
7 Mar 24
4
Ori Gutwerg
7 Mar 24
4
Christopher Mutz
7 Mar 24
4
Muthusamy Shanmugam
7 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
4
Christopher Mutz
6 Mar 24
4
Antonio R Pera
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Muthusamy Shanmugam
1 Mar 24
4
Christopher Mutz
1 Mar 24